AI316807 Activators
AI316807 Activators are a collection of chemical entities that facilitate the upregulation of AI316807's functional activity through distinct signaling mechanisms. Forskolin, by raising intracellular cAMP, indirectly promotes AI316807's activity by enhancing PKA signaling, which may subsequently phosphorylate and activate AI316807. IBMX, through its inhibition of phosphodiesterases, stabilizes cAMP levels, further potentiating PKA-mediated activation pathways for AI316807. Epigallocatechin gallate serves to relieve AI316807 from negative regulatory effects by inhibiting specific protein kinases, presuming that these kinases serve to suppress AI316807 activity. On the other hand, Sphingosine-1-phosphate through its receptor-mediated signaling can activate PI3K/Akt pathways, which might lead to the activation of AI316807 if it is downstream of or modulated by these pathways.
AI316807 Activators encompass a range of chemical compounds that bolster the functional activity of AI316807 through various targeted cellular mechanisms. Forskolin and IBMX orchestrate an increase in intracellular cAMP levels, with Forskolin directly stimulating adenylyl cyclase, and IBMX preventing cAMP degradation, thereby enhancing AI316807 activity through PKA-dependent phosphorylation, assuming AI316807's functionality is modulated by such phosphorylation. The polyphenol Epigallocatechin gallate acts as a kinase inhibitor, potentially reducing inhibitory phosphorylation on AI316807, leading to its enhanced activity. Similarly, Sphingosine-1-phosphate activates G protein-coupled receptor-mediated signaling pathways like PI3K/Akt, which could indirectly augment AI316807 activity if it operates downstream of these pathways. Additionally, PMA, as a PKC activator, may directly phosphorylate AI316807 or alter its activity through PKC-regulated pathways, while LY294002 and U0126, by inhibiting PI3K and MEK1/2 respectively, could upregulate alternative signaling routes that enhance AI316807 activity through a compensatory cellular response.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as a non-selective inhibitor of phosphodiesterases, preventing cAMP degradation, which can result in the sustained activation of PKA and subsequent phosphorylation of target proteins including potentially AI316807. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate inhibits various protein kinases, potentially reducing negative regulatory phosphorylation events and thereby enhancing the activity of AI316807 if it is negatively regulated by such kinases. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate interacts with its G protein-coupled receptors to modulate signaling pathways such as PI3K/Akt, potentially enhancing AI316807 activity through these signaling cascades if AI316807 is regulated by them. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate and activate AI316807 directly or through downstream signaling pathways if AI316807 is PKC-responsive. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could lead to a compensatory upregulation of alternative pathways that activate AI316807, assuming AI316807 is part of a feedback mechanism that compensates for PI3K pathway inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, leading to decreased ERK phosphorylation. This could enhance AI316807's activity if AI316807 is part of a signaling cascade that is activated as a compensatory response to reduced MAPK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which may lead to the activation of alternative pathways, potentially enhancing the activity of AI316807 if it is involved in response pathways to p38 MAPK inhibition. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, potentially enhancing AI316807 activity by activating calcium-dependent signaling if AI316807 is regulated by such signaling. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels, which could enhance AI316807 activity through calcium-dependent signaling pathways. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a membrane-permeable cAMP analog that directly elevates intracellular cAMP levels, potentially enhancing AI316807 activity through cAMP-dependent PKA activation if AI316807 is cAMP-responsive. | ||||||